Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Varsha Gandhi, PhD, on Ibrutinib

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Advertisement

Advertisement




Aug
10
Today In Oncology
Kinase Inhibitor Approved for Nonsquamous NSCLC With HER2 TKD–Activating Mutations
Potential New Second-Line Standard of Care Emerges in Small Cell Lung Cancer
Mortality in Advanced-Stage Ovarian Cancer—Effect of Neoadjuvant Chemotherapy and Cytoreductive Surgery Case Volume
Smoking Cessation in Cancer Care: Challenges and Opportunities
GLP-1 Receptor Agonists vs Other Glucose-Lowering Drugs: Survival in Older Patients With Cancer and Diabetes
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo